GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spectrum Pharmaceuticals Inc (NAS:SPPI) » Definitions » 10-Year ROIIC %

Spectrum Pharmaceuticals (Spectrum Pharmaceuticals) 10-Year ROIIC % : 62.83% (As of Dec. 2022)


View and export this data going back to 1996. Start your Free Trial

What is Spectrum Pharmaceuticals 10-Year ROIIC %?

10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year. Spectrum Pharmaceuticals's 10-Year ROIIC % for the quarter that ended in Dec. 2022 was 62.83%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Spectrum Pharmaceuticals's 10-Year ROIIC % or its related term are showing as below:

SPPI's 10-Year ROIIC % is not ranked
in the Biotechnology industry.
Industry Median: -34.68 vs SPPI: 62.83

Spectrum Pharmaceuticals 10-Year ROIIC % Historical Data

The historical data trend for Spectrum Pharmaceuticals's 10-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spectrum Pharmaceuticals 10-Year ROIIC % Chart

Spectrum Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
10-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -111.45 423.09 256.28 273.49 62.83

Spectrum Pharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
10-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 62.83 -

Competitive Comparison of Spectrum Pharmaceuticals's 10-Year ROIIC %

For the Biotechnology subindustry, Spectrum Pharmaceuticals's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spectrum Pharmaceuticals's 10-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spectrum Pharmaceuticals's 10-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Spectrum Pharmaceuticals's 10-Year ROIIC % falls into.



Spectrum Pharmaceuticals 10-Year ROIIC % Calculation

Spectrum Pharmaceuticals's 10-Year ROIIC % for the quarter that ended in Dec. 2022 is calculated as:

10-Year ROIIC %=10-Year Incremental Net Operating Profit After Taxes (NOPAT)**/10-Year Incremental Invested Capital**
=( -72.7406182 (Dec. 2022) - 95.192159 (Dec. 2012) )/( 6.17 (Dec. 2022) - 273.447 (Dec. 2012) )
=-167.9327772/-267.277
=62.83%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Spectrum Pharmaceuticals  (NAS:SPPI) 10-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Spectrum Pharmaceuticals 10-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Spectrum Pharmaceuticals's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Spectrum Pharmaceuticals (Spectrum Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Pilot House - Lewis Wharf, 2 Atlantic Avenue, 6th Floor, Boston, MA, USA, 02110
Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. It is a biopharmaceutical company with a primary strategy comprised of acquiring, developing and commercializing novel and targeted oncology therapies. Eflapegrastim and Poziotinib are it's current drugs in last stage development. Eflapegrastim is a novel long-acting granulocyte colony-stimulating factor ("G-CSF") for the treatment of chemotherapy-induced neutropenia and Poziotinib is a novel irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer ("NSCLC") tumors with various mutations. It has one segment that is focused exclusively on developing and marketing oncology and hematology drug products.
Executives
Juhyun Lim director 11500 S. EASTERN AVE., SUITE 220, HENDERSON NV 89052
Fischer Seth H.z. director C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Brittany Bradrick director C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Nora Brennan officer: See Remarks C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Keith M Mcgahan officer: Chief Legal Officer 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Thomas J Riga director, officer: CEO & President 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Jeff L Vacirca director 4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO CA 92121
Francois Lebel officer: Chief Medical Officer 4100 LEXINGTO AVE N, ARDEN HILLS MN 55126-2998
Dolatrai Vyas director 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Kurt A Gustafson officer: EVP & Chief Financial Officer 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Joseph W. Turgeon officer: Chief Commercial Officer 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Elizabeth Czerepak director 201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Maida Anthony E Iii director 157 TECHNOLOGY DR, IRVINE CA 92618
Stuart Mitchell Krassner director 157 TEHCNOLOGY DRIVE, IRVINE CA 92618

Spectrum Pharmaceuticals (Spectrum Pharmaceuticals) Headlines

From GuruFocus